Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Teleflex (NYSE:TFX) in the last three months. The table below provides a snapshot of their ...

Teleflex's TFX robust performance in the Interventional product line is poised to help it grow in the upcoming quarters. The Urolift system is seeing consistent growth in hospitals, with positive ...

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...

Teleflex stock (NYSE: TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a 31% fall this year, underperforming the broader S&P500 index, ...

Shares of medical technology company Teleflex (NYSE:TFX) fell 22.9% in the morning session after the company reported ...

Teleflex is a medical device and instrument manufacturer with $3 billion in sales, supplying a wide range of products. The company saw strong growth in the 2010s as growth slowed down in recent years.

Teleflex (NYSE:TFX) is slated for expansion in the coming quarters, owing to the key growth drivers in the Interventional business. The company's market dominance in Central Venous Catheters and ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Teleflex stock (NYSE: TFX), which provides instruments and consumables for laboratories, trades at $220 per share, 50% below the level seen in March 2021. TFX stock was trading at around $246 in early ...

Teleflex focuses on the sale of medical technology products, generally used in hospitals and health centers. I think that development and innovation in new products, expansion of technologies, and the ...